Moreover, in multiple preclinical models, including melanoma, pancreatic adenocarcinoma, and hepatocellular carcinoma, PDE5 inhibitors have demonstrated synergy with immune checkpoint blockade, further supporting their potential as immunomodulatory adjuncts in cancer therapy (14, 15, 22). Here, PDE5A is linked to pancreatic adenocarcinoma.